Abstract: A vehicle seating assembly includes a seat base operably coupled with a seatback and an anchor housing operably coupled with one of the seat base and the seatback. The anchor housing includes a body defining a cavity and a slot in communication with the cavity. First and second sidewalls of the body define first and second receiving wells, respectively. A cam includes first and second arms that include first and second protrusions, respectively. The first and second protrusions are configured to be received by the first and second receiving wells, respectively. The cam is positioned within the cavity of the body and is rotatable between an open position and a closed position. An anchor extends between the seat base and the seatback and is operably coupled with the anchor housing when the cam is in the closed position.

Abstract: A lubricant additive concentrate containing 30 to 80 mass % oil of lubricating viscosity and from 20 to 70 mass % of additive; wherein from 30 to 90 mass % of the additive is (i) hybrid overbased colloidal detergent derived from sulfonate surfactant and hydroxybenzoate surfactant; and (ii) polyalkenyl succinimide dispersant derived from a polyalkene having a number average molecular weight (Mn) of from 1300 to 2500 daltons, and wherein the mass ratio of polyalkenyl succinimide dispersant (ii) to hybrid overbased colloidal detergent (i) in the lubricant additive is from 25:1 to 1:1.

Abstract: An overbased magnesium sulfonate detergent is made by (A) preparing a mixture of a sulfonic acid or salt with a magnesium oxide, water, a C1-C5 alkanol, a hydrocarbon solvent, and a combination of a polyisobutene succinic anhydride of molecular weight (Mw) 500 to 1500 g mol?1 and a salicylic acid as first and second promoters; and (B) carbonating the mixture with an acidic gas to form the overbased magnesium sulfonate.

Abstract: A lubricant additive concentrate containing 30 to 80 mass % oil of lubricating viscosity and from 20 to 70 mass % of additive; wherein from 30 to 90 mass % of the additive is (i) hybrid overbased colloidal detergent derived from sulfonate surfactant and hydroxybenzoate surfactant; and (ii) polyalkenyl succinimide dispersant derived from a polyalkene having a number average molecular weight (Mn) of from 1300 to 2500 daltons, and wherein the mass ratio of polyalkenyl succinimide dispersant (ii) to hybrid overbased colloidal detergent (i) in the lubricant additive is from 25:1 to 1:1.

Abstract: A wet friction clutch—lubricant system wherein a wet friction clutch having a cellulose—based friction lining having a surface coating of silica based particles, or a device including such a clutch, is lubricated with a lubricant composition a major amount of oil of lubricating viscosity and minor effective amounts of performance enhancing additives including (a) ashless dispersant; (b) organic phosphorus compound and (c) borated detergents; and optionally, (d) an auxiliary friction modifier.

Abstract: A restraint system for a removable vehicle seat is attached to the vehicle seat. A restraint tower associated with the restraint system transfers energy generated during vehicle impact.

Abstract: A method of improving the compatibility of an overbased detergent with other additives in a lubricating oil composition. The method includes the step of the using a detergent have a degree of carbonation of greater than 85%.

Abstract: A portion of a riser of a removable vehicle seat has a layered structure. The layered structure provides abrasion resistance and noise isolation.

Abstract: A wet friction clutch—lubricant system wherein a wet friction clutch having a cellulose—based friction lining having a surface coating of silica based particles, or a device including such a clutch, is lubricated with a lubricant composition a major amount of oil of lubricating viscosity and minor effective amounts of performance enhancing additives including (a) ashless dispersant; (b) organic phosphorus compound and (c) borated detergents; and optionally, (d) an auxiliary friction modifier.

Abstract: A wet friction clutch-lubricant system wherein a wet friction clutch having a cellulose-based friction lining, or a device including such a clutch, is lubricated with a lubricant composition a major amount of oil of lubricating viscosity and minor effective amounts of performance enhancing additives including (a) one or more ashless dispersant; (b) one or more organic phosphorus compound and (c) one or more sodium salt of an organic acid; and optionally, (d) an auxiliary friction modifier.

Abstract: A lubricating oil composition comprising (A) an oil of lubricating viscosity; and, (B) as an additive component, an oil-soluble mixture of oxyalkylated hydrocarbyl phenol condensates wherein the oxyalkyl groups have the formula —(R?O)n— where R? is an ethylene, a propylene or a butylene group; n is independently from 0 to 10; less than 45 mole % of the phenolic hydroxyl groups in the mixture are not oxyalkylated; and more than 55 mole % of the oxyalkyl groups in the mixture have the formula —R?O— where n is 1.

Abstract: A method of improving the compatibility of an overbased detergent with other additives in a lubricating oil composition. The method includes the step of the using a detergent have a degree of carbonation of greater than 85%.

Abstract: A portion of a riser of a removable vehicle seat has a layered structure. The layered structure provides abrasion resistance and noise isolation.

Abstract: A restraint system for a removable vehicle seat is attached to the vehicle seat. A restraint tower associated with the restraint system transfers energy generated during vehicle impact.

Abstract: A structural member for a removable vehicle seat provides integrated attachment features for a flex-mat, risers, and restraint system.

Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of ?-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

Abstract: The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like.

Abstract: The present invention relates to certain pyrazole carboxylic acid and ester derivatives, and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the RUP25 receptor. (I) Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like.

Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of ?-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

Abstract: The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like.